Article

Dr. Mims Discusses Momelotinib in Myelofibrosis

Author(s):

Alice S. Mims, MD

Alice S. Mims, MD, assistant professor of medicine, The Ohio State University Comprehensive Cancer Center, discusses momelotinib in patients with myelofibrosis.

Alice S. Mims, MD, assistant professor of medicine, The Ohio State University Comprehensive Cancer Center, discusses momelotinib in patients with myelofibrosis.

The SIMPLIFY-1 study investigated momelotinib to determine if it was non-inferior to ruxolitinib (Jakafi). It did show non-inferiority of splenic size for patients with myelofibrosis, states Mims.

The SIMPLIFY-2 attempted to determine if momelotinib was superior to ruxilitinib. It was not superior but there was improvement in anemia. There will be some role for momelotinib in the future for these patients, states Mims.

Related Videos
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS
Related Content
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
November 15th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA
November 14th 2024

FDA Approves Nilotinib Tablets Without Mealtime Restrictions for CML

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
November 13th 2024

Real-World Experience With CAR T Varies From Trials in DLBCL

Pacritinib in myelofibrosis Image credit: Ifti Digital– stock.adobe.com
November 13th 2024

Retrospective Data Show Pacritinib Improves TSS in Transfusion-Dependent Myelofibrosis